Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial

Esperion Therapeutics (ESPR) Stock Forecast & Price Target

$2.36
+0.02 (+0.85%)
(As of 01:48 PM ET)

Esperion Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$8.83
274.29% Upside
High Forecast$16.00
Average Forecast$8.83
Low Forecast$2.50
TypeCurrent Forecast
7/4/23 to 7/3/24
1 Month Ago
6/4/23 to 6/3/24
3 Months Ago
4/5/23 to 4/4/24
1 Year Ago
7/4/22 to 7/4/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$8.83$9.33$9.33$11.44
Forecasted Upside274.29% Upside317.04% Upside316.29% Upside160.52% Upside

ESPR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ESPR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Esperion Therapeutics Stock vs. The Competition

TypeEsperion TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.71
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside277.49% Upside1,116.77% Upside12.05% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/28/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00+280.95%
6/28/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00+592.64%
6/20/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$2.90 ➝ $2.50-8.09%
11/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral
8/1/2023Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnder Perform ➝ Market Perform
3/7/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral$6.50 ➝ $7.00+37.93%
The Only Retirement Stock You'll Ever Need? Discover Now (Ad)

There is a little region of America called Loudoun County. The value of each square mile has shot up close to $10 billion... It's also the source of the single greatest investment opportunity of our generation...

Get all the urgent details here >>>
3/6/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform$15.00+136.59%
2/24/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$12.00+105.83%
2/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight$9.00+52.03%
8/9/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$13.00+103.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:10 PM ET.

ESPR Forecast - Frequently Asked Questions

What is Esperion Therapeutics's stock forecast and purchase recommendation?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Esperion Therapeutics is $8.83, with a high forecast of $16.00 and a low forecast of $2.50. The consensus rating for Esperion Therapeutics stock is Hold based on the current 1 sell rating, 2 hold ratings and 2 buy ratings for ESPR. Learn more on ESPR's analyst rating history.

Do Wall Street analysts like Esperion Therapeutics more than its competitors?

Analysts like Esperion Therapeutics less than other "medical" companies. The consensus rating for Esperion Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ESPR compares to other companies.

Is Esperion Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Esperion Therapeutics's stock had 1 downgrade by analysts.

Does Esperion Therapeutics's stock price have much upside?

According to analysts, Esperion Therapeutics's stock has a predicted upside of 271.67% based on their 12-month stock forecasts.

What analysts cover Esperion Therapeutics?

Esperion Therapeutics has been rated by research analysts at Bank of America, HC Wainwright, and Needham & Company LLC in the past 90 days.


This page (NASDAQ:ESPR) was last updated on 7/3/2024 by MarketBeat.com Staff

From Our Partners